In-vitro Experimental Study About Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Sepsis
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Subcellular location of Nuclear Factor-KAPPA B p65 subunit
Study Overview
Brief Summary
Sepsis is a major cause of death in intensive care units. Despite the investigators improved understanding, which has reduced the risk of dying with sepsis, the number of people who die each year continues to increase due to an overall increase in the number of cases.In our previous study, the investigators have showed that 100% oxygen or 0.5 minimum alveolar concentration (MAC) isoflurane/sevoflurane in 60% oxygen protect mouse macrophage cell line against in-vitro sepsis induced by lipopolysaccharide (LPS).
In this study, the investigator hypothesized that treatment of 100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen protected against clinical in-vitro models of sepsis induced by LPS or plasma from septic patients.
Detailed Description
100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen would inhibit increases of tumor necrosis factor (TNF)-alpha, interleukin-1beta, interleukin-6 in the cell culture supernatant after stimulation of LPS or plasma from septic patients, and also inhibit the nuclear location of nuclear factor-kappa B p65 subunit.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Human PBMCs were only isolated from the adult patients without sepsis/SIRS/infectious diseases.
- •The plasma for induction of clinical in-vitro sepsis, was only isolated from adult patients with sepsis.
Exclusion Criteria
- •Patients who had been selected for other clinical trials in the 3 months before.
Arms & Interventions
oxygen plus isoflurane/sevoflurane
All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.
The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.
Intervention: oxygen (Drug)
oxygen plus isoflurane/sevoflurane
All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.
The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.
Intervention: Sevoflurane (Drug)
oxygen plus isoflurane/sevoflurane
All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.
The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.
Intervention: Isoflurane (Drug)
Outcomes
Primary Outcomes
Subcellular location of Nuclear Factor-KAPPA B p65 subunit
Time Frame: within 10 hours after the intervention
Secondary Outcomes
- tumor necrosis factor-alpha(within 10 hours after the intervention)
- interleukin- 1 beta(within 10 hours after the intervention)
- interleukin 6(within 10 hours after the intervention)
Investigators
Lichao Hou
M.D., Ph.D
Air Force Military Medical University, China